Literature DB >> 15969573

An efficient, stereocontrolled synthesis of a potent omuralide-salinosporin hybrid for selective proteasome inhibition.

Leleti Rajender Reddy1, Jean-François Fournier, B V Subba Reddy, E J Corey.   

Abstract

A short and highly stereocontrolled synthesis of the potent proteasome inhibitor 3 from the (S)-threonine-derived oxazoline 4 has been developed. The synthetic sequence is summarized in Scheme 1. Aldol coupling of the zinc enolate of 4 with isobutyraldehyde and subsequent silylation provided the TBS ether 5 diastereoselectively (10:1). Reductive cleavage of the oxazoline ring of 5 followed by Swern oxidation of the resulting amino alcohol afforded amino ketone 6, converted further by N-acylation to the acrylamide 7, whose structure was confirmed by X-ray crystallographic analysis. Acrylamide 7 was cyclized to 8 by a novel application of the Kulinkovich Ti(II)-cyclopentene complex. Silylation of 8 to 9 and radical cyclization at low temperature produced the bicyclic lactam 10 with complete control of all stereocenters. Hydroxy desilylation and N-deprotection of 10 gave the dihydroxy ester 11, which was converted to 3 by a novel three-step sequence: (1) demethylation with [Me2AlTeMe]2, (2) combined beta-lactonization and chlorination, and (3) desilylation to effect cleavage of the TBS ether.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969573     DOI: 10.1021/ja052376o

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  13 in total

Review 1.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Angew Chem Int Ed Engl       Date:  2010-12-03       Impact factor: 15.336

2.  Engineered biosynthesis of antiprotealide and other unnatural salinosporamide proteasome inhibitors.

Authors:  Ryan P McGlinchey; Markus Nett; Alessandra S Eustáquio; Ratnakar N Asolkar; William Fenical; Bradley S Moore
Journal:  J Am Chem Soc       Date:  2008-05-31       Impact factor: 15.419

3.  Total Synthesis of (-)-Salinosporamide A via a Late Stage C-H Insertion.

Authors:  Hadi Gholami; Aman Kulshrestha; Olivia K Favor; Richard J Staples; Babak Borhan
Journal:  Angew Chem Int Ed Engl       Date:  2019-04-10       Impact factor: 15.336

Review 4.  The marine actinomycete genus Salinispora: a model organism for secondary metabolite discovery.

Authors:  Paul R Jensen; Bradley S Moore; William Fenical
Journal:  Nat Prod Rep       Date:  2015-05       Impact factor: 13.423

Review 5.  Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.

Authors:  Barbara C Potts; Kin S Lam
Journal:  Mar Drugs       Date:  2010-03-25       Impact factor: 5.118

Review 6.  Chasing the treasures of the sea - bacterial marine natural products.

Authors:  Tobias A M Gulder; Bradley S Moore
Journal:  Curr Opin Microbiol       Date:  2009-05-28       Impact factor: 7.934

7.  (S)-4-Trimethylsilyl-3-butyn-2-ol as an auxiliary for stereocontrolled synthesis of salinosporamide analogs with modifications at positions C2 and C5.

Authors:  Landy K Blasdel; DongEun Lee; Binyuan Sun; Andrew G Myers
Journal:  Bioorg Med Chem Lett       Date:  2013-09-30       Impact factor: 2.823

Review 8.  Advances in and applications of proteasome inhibitors.

Authors:  Bradley S Moore; Alessandra S Eustáquio; Ryan P McGlinchey
Journal:  Curr Opin Chem Biol       Date:  2008-07-24       Impact factor: 8.822

9.  Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.

Authors:  Markus Nett; Tobias A M Gulder; Andrew J Kale; Chambers C Hughes; Bradley S Moore
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

10.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.